Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Diabetes, Gestational D016640 8 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Systemic Inflammatory Response Syndrome D018746 4 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Coronary Stenosis D023921 6 associated lipids
Bacteremia D016470 9 associated lipids
Arteriosclerosis Obliterans D001162 8 associated lipids
Thromboangiitis Obliterans D013919 4 associated lipids
Menorrhagia D008595 4 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Würtz M et al. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. 2010 Heart pmid:19910291
Koeberle A et al. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. 2010 J. Pharmacol. Exp. Ther. pmid:19934399
Armstrong PC et al. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. 2010 J. Thromb. Haemost. pmid:19995405
Alusik S et al. The inhibitory effect of statins on urinary 11-dehydrothromboxane levels. 2010 Int Angiol pmid:20502413
Mangalpally KK et al. Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro. 2010 J. Thromb. Thrombolysis pmid:20502945
Cholette JM et al. Aspirin resistance following pediatric cardiac surgery. 2010 Thromb. Res. pmid:20550971
Youssef DT et al. New anti-inflammatory sterols from the Red Sea sponges Scalarispongia aqabaensis and Callyspongia siphonella. 2010 Nat Prod Commun pmid:20184014
Yassine HN et al. Clinical determinants of aspirin resistance in diabetes. 2010 Diabetes Res. Clin. Pract. pmid:20719400
Würtz M et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. 2010 JACC Cardiovasc Interv pmid:20723855
Kim SY et al. Platelet anti-aggregation activities of compounds from Cinnamomum cassia. 2010 J Med Food pmid:20828311
Bao YM et al. [Effect of precondition with GBE50 and Salviae miltionrrhizae on cycloxygenase-2 and its downstream effectors contents in ischemia/reperfusion myocardium]. 2010 Zhongguo Zhong Xi Yi Jie He Za Zhi pmid:21066890
De la Cruz JP et al. Differences in the in vitro antiplatelet effect of dexibuprofen, ibuprofen, and flurbiprofen in human blood. 2010 Anesth. Analg. pmid:21048099
Wang BZ et al. [Association of Rs10487667 genetic polymorphism of thromboxane synthase with myocardial infarction in Uigur population of Xinjiang]. 2010 Zhonghua Yu Fang Yi Xue Za Zhi pmid:21215134
Ge Y et al. [Effect of ulinastatin on thromboxane Bâ‚‚ and deep vein thrombosis in elderly patients after hip joint replacement]. 2010 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:21200097
Dołegowska B et al. Dynamics of thromboxane level changes during early phase of allograft reperfusion. 2009 Sep-Oct Clin Transplant pmid:19298388
Tantry US et al. Aspirin resistance. 2009 Sep-Oct Prog Cardiovasc Dis pmid:19732606
Thomson VS et al. Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events. 2009 Oct-Dec J Postgrad Med pmid:20083870
Goodman L et al. Effects of firocoxib and tepoxalin on healing in a canine gastric mucosal injury model. 2009 Jan-Feb J. Vet. Intern. Med. pmid:19175721
Frelinger AL et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. 2009 Circulation pmid:19996015
Kambara T et al. Propofol suppresses prostaglandin E(2) production in human peripheral monocytes. 2009 Immunopharmacol Immunotoxicol pmid:19951072
Hu Y et al. Chinese herbal medicinal ingredients inhibit secretion of IL-6, IL-8, E-selectin and TXB2 in LPS-induced rat intestinal microvascular endothelial cells. 2009 Immunopharmacol Immunotoxicol pmid:19874221
Li M et al. Effects of pathological flow on pulmonary artery endothelial production of vasoactive mediators and growth factors. 2009 J. Vasc. Res. pmid:19571576
McClelland S et al. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. 2009 Atherosclerosis pmid:18514659
Coates AM et al. Regular consumption of n-3 fatty acid-enriched pork modifies cardiovascular risk factors. 2009 Br. J. Nutr. pmid:18590592
Xu Y et al. Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors. 2009 Br. J. Pharmacol. pmid:19572944
Zhao L et al. Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. 2009 Br. J. Pharmacol. pmid:19220291
Shah KB et al. The cardioprotective effects of fish oil during pressure overload are blocked by high fat intake: role of cardiac phospholipid remodeling. 2009 Hypertension pmid:19597033
Ulbrich SE et al. Quantitative characterization of prostaglandins in the uterus of early pregnant cattle. 2009 Reproduction pmid:19470711
Santilli F et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". 2009 J. Am. Coll. Cardiol. pmid:19232899
Lev EI Aspirin resistance transient laboratory finding or important clinical entity? 2009 J. Am. Coll. Cardiol. pmid:19232900
Bernoud-Hubac N et al. Low concentrations of reactive gamma-ketoaldehydes prime thromboxane-dependent human platelet aggregation via p38-MAPK activation. 2009 Biochim. Biophys. Acta pmid:19233311
Giraudel JM et al. Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib. 2009 J. Vet. Pharmacol. Ther. pmid:19161453
Jespersen B et al. Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo. 2009 Nephrol. Dial. Transplant. pmid:19193738
Chen SS et al. Elevated plasma prostaglandins and acetylated histone in monocytes in Type 1 diabetes patients. 2009 Diabet. Med. pmid:19236624
Kanazawa S et al. Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer. 2009 Platelets pmid:19172526
Calapai G et al. Cardiovascular biomarkers in groups of established smokers after a decade of smoking. 2009 Basic Clin. Pharmacol. Toxicol. pmid:19175368
Kapetanovic IM et al. Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats. 2009 Chem. Biol. Interact. pmid:18992230
Basselin M et al. Imaging elevated brain arachidonic acid signaling in unanesthetized serotonin transporter (5-HTT)-deficient mice. 2009 Neuropsychopharmacology pmid:19145225
Dołegowska B et al. Platelets arachidonic acid metabolism in patients with essential hypertension. 2009 Platelets pmid:19440924
Ahmad M et al. Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity. 2009 Brain Res. pmid:19446533
Mayer K et al. Acute lung injury is reduced in fat-1 mice endogenously synthesizing n-3 fatty acids. 2009 Am. J. Respir. Crit. Care Med. pmid:19136374
Schuijt MP et al. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. 2009 Br. J. Pharmacol. pmid:19466986
Eriksson AC et al. Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study. 2009 J Transl Med pmid:19508722
Cattaneo M Letter by cattaneo regarding article, "incomplete inhibition of thromboxane biosynthesis by acetylsalicylic Acid: determinants and effect on cardiovascular risk". 2009 Circulation pmid:19546394
Schiff M et al. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. 2009 Curr Med Res Opin pmid:19678751
Cook VL et al. Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum. 2009 Am. J. Vet. Res. pmid:19645580
Blais N et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). 2009 Thromb. Haemost. pmid:19652893
Zhang X et al. Effect of baicalin on inflammatory mediator levels and microcirculation disturbance in rats with severe acute pancreatitis. 2009 Pancreas pmid:19657312
Liu FC et al. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase. 2009 Biochem. Pharmacol. pmid:19426675
Peng CY et al. Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease. 2009 Exp. Biol. Med. (Maywood) pmid:19429858